Revenue Recognition and Collaborative Arrangements (Tables)

9 Months Ended

Sep. 30, 2021

Revenue Recognition and Collaborative Arrangements

Schedule of net revenue from collaborative arrangements

Net revenue recognized under our GSK Agreements was as follows:

	Three Months Ended September 30,						Nine Months Ended September 30,
(In thousands)	2021			2020			2021			2020
Royalties from a related party    - RELVAR/BREO	$	54,092		$	63,893		$	176,398		$	165,612
Royalties from a related party    - ANORO		11,641			11,882			34,101			32,931
Royalties from a related party    - TRELEGY		35,585			16,375			84,055			48,143
Total royalties from a related party		101,318			92,150			294,554			246,686
Less: amortization of capitalized fees    paid to a related party		(3,456	)		(3,456	)		(10,368	)		(10,368	)
Royalty revenue		97,862			88,694			284,186			236,318
Strategic alliance - MABA program		—			—			—			10,000
Total net revenue from GSK	$	97,862		$	88,694		$	284,186		$	246,318